Overview

• Healthcare technology firm's fiscal Q4 revenue rose 9.9% yr/yr to $9.81 bln

• Fiscal Q4 adjusted EPS was $1.55, GAAP EPS was $0.96

• Company raised quarterly dividend

Outlook

• Medtronic guides to FY27 organic revenue growth of 6.75% to 7.25%

• Company expects FY27 diluted non-GAAP EPS of $5.90 to $6.00

• Medtronic says it enters FY27 with strong momentum and a resilient operating foundation

Result Drivers

• CARDIOVASCULAR GROWTH - Q4 revenue was driven by 10.1% organic growth in Cardiovascular, led by Cardiac Rhythm Management and new product launches such as OmniaSecure, per company

• MEDICAL SURGICAL & DIABETES - Medical Surgical revenue rose 5.1% organically, supported by growth in Acute Care & Monitoring and Endoscopy, while Diabetes revenue increased 8.1% organically

Company press release: ID:nPn1D09C8a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		$9.81 bln
Q4 Adjusted EPS		$1.55
Q4 EPS		$0.96

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Medtronic PLC is $108.00, about 46.4% above its June 2 closing price of $73.75

• The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.